Home

Mda5 antibody positive

We evaluated the association between 1-year survival rate and PE for refractory RP-ILD in patients positive for anti-MDA5 antibodies. Intensive immunosuppressive therapy improved the survival rate in RP-ILD patients with anti-MDA5 antibodies, but 20-30% of cases were still fatal. PE could be adminis Anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive clinically amyopathic dermatomyositis (CADM) is frequently associated with rapidly progressive interstitial lung disease (RP-ILD) resulting in high mortality Melanoma differentiation-associated protein 5 (MDA5) antibody-positive dermatomyositis (DM) displays unique cutaneous and pathologic features. We describe two cases of myositis-associated rapidly progressive interstitial lung disease (RP-ILD). The patients were two women from Kerala, India. Both patients had anti-MDA5 antibody-positive myositis This case report details the multidisciplinary assessment of an anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive individual with inflammatory polyarthropathy, mucocutaneous capillary changes, and evidence of interstitial lung disease but lacking overt skin and muscle disease After the diagnosis of anti-MDA5 antibody-positive DM, she was treated with intravenous steroid pulse therapy (methylprednisolone, 1,000 mg/day for 3 days), oral prednisolone at 1.0 mg/kg/day, and tacrolimus at 4.0 mg/day. The lesions of panniculitis associated with DM/CADM typically present on the buttocks, thighs, arms, and abdomen

Anti-MDA5 antibody-positive amyopathic dermatomyositis is a subtype of dermatomyositis where there is positivity to an anti-melanoma differentiation-associated gene 5 (MDA5) antibody. It has been reported to be associated with rapidly progressive interstitial lung disease (RP-ILD) resulting in high mortality Antinuclear antibodies were negative but intense positivity of anti-MDA5 antibodies was found. Liver and muscle enzymes as well as numbers of blood cells and ferritin levels were normal (Table 1), whereas ESR was mildly increased (Table 1) In support of this view, we would like to highlight the striking similarities between COVID-19 and a rare autoimmune disease: the anti-MDA5-syndrome. The hallmark of this disease is the presence of auto-antibodies targeting MDA5, an intracellular sensor of viral RNA (including coronavirus) that triggers the innate immune response

Successful treatment of anti-MDA5 antibody-positive

Effective Administration of Rituximab in Anti-MDA5 Antibody-Positive Dermatomyositis with Rapidly Progressive Interstitial Lung Disease and Refractory Cutaneous Involvement: A Case Report and Literature Review. Ogawa Y(1), Kishida D(1), Shimojima Y(1), Hayashi K(2), Sekijima Y(1) In summary, patients with anti‐MDA5 antibody‐positive CADM usually present with respiratory symptoms with rapid deterioration or RP‐ILD. As RP‐ILD is associated with a high mortality rate, an early diagnosis is important to initiate treatment in these patients Not only is MDA5-positive RP-ILD a rare cause of ILD, but the ILD often results in significant morbidity and mortality. Although there are several proposed treatment regimens, patients often succumb to the illness despite initiation of therapy. As such, early diagnosis and treatment in these patients is of paramount importance Researchers identified 3 groups of patients with positive anti-MDA5 antibody with different prognoses. Cluster 1 included 15 patients (18.1%) who had rapidly progressive ILD

RP-ILD in patients positive for anti-MDA5 antibodies is among the most fatal and treatment-refractory diseases. Over 10 years ago, the mortality rate following conventional therapy was reported to be almost 25%, and Nakashima et al. reported that intensive immunosuppressive therapy improved the 6-month survival rate to almost 75% [ 2 ] The anti-MDA5 antibody is a characteristic myositis-specific autoantibody associated with CADM and IP, which may cause a poor prognosis. CADM complicated with malignancy occurs less frequently than similarly complicated dermatomyositis and, to the best of our knowledge, this is the first case of CADM complicated with two cancers MDA5 antibody-positive CADM with IP is resistant to treatment, and DM with malignancy usually responds poorly to immunosuppressive therapy[10]. A case of anti-MDA5 antibody-positive CADM complicated with IP and two cancers which could be successfully treated has never been reported to our knowledge. We considered the possible causes o Conclusion: Anti-MDA5 antibody-positive DM patients showed high T1-IFN signatures in serum and affected skin. The high T1-IFN signatures of the MDA5 antibody-positive DM patients in serum and deep vasculatures suggested that T1-IFN may have important roles in the vasculopathy of these patients

CADM patients with the anti-MDA5 antibody (anti-MDA5ab) frequently develop the complication of RP-ILD, especially in Japan [ 7-10 ]. Sato et al. [ 7] identified melanoma differentiation-associated gene 5 (MDA5) as the CADM-140 antigen. The MDA5 protein plays a role in the innate immune response Compared with patients who were anti-MDA5 antibody negative, those who were antibody positive demonstrated more frequent dermatitis, clinically amyopathic DM, interstitial lung disease and rapid-progressive interstitial lung disease, as well as significantly higher serum ferritin, significantly lower creatine kinase and aldolase, and significantly less frequent ANA (⩾1:160) and anti-cytoplasmic pattern of ANA staining positivity

Anti-MDA5 Ab-positive DM patients had a lower relapse rate during the 2 years after the initial treatment compared to other DM patients. However, it has been only about 10 years since DM patients with anti-MDA5 antibody-positive were well recognized. Although our patient's case indicates the possibility that ILD can be recurred after long-term. Anti-MDA5 antibody-positive dermatomyositis presenting as unilateral eyelid edema Lauren Chen, MS, Kyle Owens, MD, and Andrea Murina, MD New Orleans, Louisiana Key words: anti-MDA5 antibody; dermatomyositis; rapidly progressive interstitial lung disease. INTRODUCTION Dermatomyositis (DM) is an idiopathic inflamma Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Rheumatology. 2012; 51: 1563-1570 View in Article Scopus (141 Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis Rheumatology (Oxford) , 51 ( 9 ) ( 2012 ) , pp. 1563 - 157

Anti-MDA5 antibody-positive hypomyopathic dermatomyositis

As a subtype of dermatomyositis (DM), anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive DM is associated with palmar papules and cutaneous ulcerations, and an increased risk of interstitial lung disease (ILD) which can be rapidly progressive (RP-ILD), especially in China and Japan [ 1, 2, 3, 4, 5, 6 ] This case series included six adult patients with anti-MDA5 antibody-positive ILD, who were admitted to Songklanagarind Hospital, Prince of Songkla University, Thailand, between January 2018 and June 2020. All the patients were diagnosed, provided with treatments, and followed up by the rheumatologists (BS, PI) Macrophage-mannose receptor CD206 is increased in anti-melanoma differential gene 5 antibody-positive DM-associated interstitial lung disease and associated with their prognosis

Anti-MDA5 antibody-positive dermatomyositis with rapidly

Among IM patients, those with anti-melanoma differentiation-associated gene 5 (MDA5) antibody (Ab) show characteristic features with clinically amyopathic DM (CADM) and progressive ILD [ 2, 3 ]. MDA5-Ab-positive patients frequently show typical cutaneous features such as palmer papules and skin ulcers due to severe vasculopathy [ 4 ] Anti-MDA5 antibody-positive amyopathic dermatomyositis is a subtype of dermatomyositis where there is positivity to an anti-melanoma differentiation-associated gene 5 (MDA5) antibody. It has been reported to be associated with rapidly progressive interstitial lung disease (RP-ILD) resulting in high mortality. On thoracic imaging, patient's may show rapidly progressive interstitial changes. Anti-MDA5 Antibody Positive Dermatomyositis Is Not Always Associated with Recalcitrant Lung Disease or Mortality. Dipekka Soni 1, David Maniscalco 2, Srihari Veeraraghavan 3, Justin Cheeley 3 and Arezou Khosroshahi 1, 1 Emory University, Atlanta, GA, 2 Emory University, Altanta, 3 Emory University, Atlanta

Anti-MDA5 Antibody-Positive Interstitial Pneumonia with

  1. MDA5 antibody-positive DM than in anti-MDA5 antibody-negative DM (12). Our three cases had features of anti-MDA5 antibody-positive dermatomyositis on HRCT, sug-gesting an association between the anti-MDA5 antibody and HRCT findings, regardless of the skin involvement in these cases. All three patients in the present series died within tw
  2. The specific type of dermatomyositis that Marcia had, however, was even less common; named MDA5 antibody positive dermatomyositis, it is more life-threatening than other forms of DM, since it affects the lungs. Only 5% of those with DM have this particular variation, making it extremely challenging to diagnose
  3. Background: Anti-melanoma differentiation-associated gene 5 antibody (anti-MDA5 Ab)-positive dermatomyositis (DM) is frequently associated with rapidly progressive interstitial pneumonia (RPIP), whose prognosis is assumed to be poor[1]. Although outcome of DM-RPIP has been reported to be improved by early immunosuppressive therapy, we still experience the cases with severe outcome
  4. Background/Purpose: The anti-melanoma differentiation-associated gene 5 antibody (MDA5) was recently classified as a myositis-specific antibody (MSA), and has been associated with rapidly progressive interstitial lung disease (ILD), amyopathic dermatomyositis (aDM), mechanic's hands, ulcerations, inflammatory arthritis, and increased mortality. This study sought to distinguish the clinical.
  5. istration of Rituximab in Anti-MDA5 Antibody-Positive Dermatomyositis with Rapidly Progressive Interstitial Lung Disease and Refractory Cutaneous Involvement: A Case Report and Literature Review , Case Reports in Rheumatology, vol. 2017, Article.

Anti-MDA5 Antibody-Positive Dermatomyositis Presenting

  1. Myositis-Specific Antibodies (MSA\'s) and others, called Myositis-Associated antibodies (MAA), were identified several years ago and can assist your doctor in helping to confirm a diagnosis of certain types of inflammatory myopathies. They are also helpful in diagnosing Antisynthetase syndrome. These antibodies also offer some insight into potential complications you may experience during the.
  2. Introduction: Patients with anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive amyopathic dermatomyositis (ADM) often develop rapidly progressive interstitial lung diseases (RP-ILD), with poor treatment success. Many studies have shown that this is the main cause of death in patients with anti-MDA5 antibody-positive ADM.Case Presentation: A 37-years-old woman developed a.
  3. Anti-MDA5 Antibody-positive Dermatomyositis is a rare subtype of DM associated with rapidly progressive ILD, higher incidence of spontaneous pneumothorax and pneumomediastinum and worse prognosis. Written informed patient consent for publication has been obtained
  4. 22. Gono T, Sato S, Kawaguchi Y, Kuwana M, Hanaoka M, Katsumata Y, et al. Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Rheumatology. (2012) 51:1563-70. doi: 10.1093/rheumatology/kes10

Clinically amyopathic dermatomyositis (CADM) with anti-melanoma differentiation-associated gene 5 antibody is associated with rapidly progressive interstitial lung disease (RP-ILD) which results in up to 50% mortality, especially within six months of diagnosis. However, limited data are available on this disease. This is the first case series. anti-MDA5 antibodies. The MDA5 protein is part of innate immune response.3-6 It elicits the production of type I immu-nity with release of interferon and tumour necrosis factor alpha, resulting in a cytokine storm. 7 This may contribute to the pathogen-esis of RP-ILD with anti-MDA5 antibody-positive DM; however Anti-MDA5 antibody was significantly associated with RP-ILD, as RP-ILD developed in 63.6% (28/44) of anti-MDA5-positive patients compared with 29.0% (49/169) of anti-MDA5-negative patients (). The incidence of death due to ILD in anti-MDA5-positive patients was 20.5% (9/44), significantly higher than that of the anti-MDA5-negative group (4.7%. A Fatal Case of Anti-MDA5 Antibody Positive Clinically Amyopathic Dermatomyositis (CADM) Associated with Rapidly Progressive Interstitial Lung Disease Abstract Send to Citation Mgr. Add to Favorites. Email to a Friend. Track Citations. A Fatal Case of Anti-MDA5 Antibody Positive Clinically Amyopathic Dermatomyositis (CADM) Associated with. Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Rheumatology 2012 ; 51 : 1563 - 70

Anti melanoma differentiation associated gene 5 (MDA5

Publication date: Jun 30, 2021Dermatomyositis with positive anti-melanoma differentiation-associated gene 5 (anti-MDA5) antibody has a distinct phenotype associated with small hand joint arthritis, mucocutaneous ulceration, palmar papules and less muscle involvement. It is also associate Prognostic evaluation of serum osteopontin in patients with anti-MDA5 antibody-positive dermatomyositis associated interstitial lung disease. Author links open overlay panel Yujuan Gao a b 1 Qi Zhao a b 1 Miaomiao Xie a 1 Xin Yan b Yan Li b Xin Zhang c Hongyan Wu d Jinghong Dai b Min Cao b Hourong Cai a b. Show more (2021). A case of anti-MDA5 antibody-positive dermatomyositis developing reversible cerebral vasospasm syndrome successfully treated by multi-immunosuppressant combination including mycophenolate mofetil. Modern Rheumatology Case Reports: Vol. 5, No. 1, pp. 69-75 Baseline features and outcomes of anti-MDA5 positive patients. A total of 90 anti-MDA5 positive patients were included in our study. The demographic features, antibody variables and treatment regimens on admission, and the clinical outcomes were recorded in Table1.The average age at disease onset was 51.9 ± 12.1 years, and female accounted for 63.3% of the cohort Background Dermatomyositis with positive anti-melanoma differentiation-associated gene 5 (anti-MDA5) antibody has a distinct phenotype associated with small hand joint arthritis, mucocutaneous ulceration, palmar papules and less muscle involvement. It is also associated with increased risk of rapidly progressive interstitial lung disease (RP-ILD) and has a high mortality rate in adults. There.

Anti-melanoma differentiation-associated gene 5 (MDA5) antibody (Ab)-positive clinically amyopathic dermatomyositis (CADM) with pneumomediastinum (PNM) is a life-threatening condition. We aim to determine the prognostic factors affecting survival of patients with anti-MDA5 Ab-positive CADM complicated with PNM. We retrospectively established a cohort of patients with anti-MDA5 Ab-positive CADM. RP-ILD is a severe complication of anti-MDA5 antibody-positive DM with an extremely poor prognosis, and several studies have demonstrated the association of high serum ferritin levels with mortality. Gono et al. reported that no patient with ferritin levels more than 1600 ng/mL survived the disease In summary, this study explores the clinical features of lipid metabolism in untreated patients with anti-MDA5 antibody-positive, deepening the understanding of this disease and providing a reliable basis for follow-up studies. Go to: Funding Statement

MDA5-positive dermatomyositis: an uncommon entity in

  1. Recognition of distinct clinical features of anti-MDA5 antibody-positive dermatomyositis and testing for MSA is crucial in patients with skin ulceration and abnormal pulmonary findings of unknown etiology, as prompt diagnosis with early aggressive treatment and anticipation of complications could make a difference in the outcome of this disease.
  2. To report our experience in using rituximab (RTX) for treating refractory rapidly progressive interstitial lung disease (RP-ILD) complicating anti-melanoma differentiation-associated gene 5 antibody (anti-MDA5 Ab)-positive amyopathic dermatomyositis (ADM). Medical records of four ADM patients with refractory RP-ILD treated with RTX therapy were reviewed retrospectively
  3. Gono T, Sato S, Kawaguchi Y, et al. Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis
  4. ation showed heliotrope rash, V-sign, photosensitive rash, and mechanic's hands.
(PDF) Anti-MDA5 Antibody-positive Dermatomyositis

Background: This is an extended report of our study [1]. Anti-melanoma differentiation-associated gene 5 (MDA5) antibodies, which are closely related to interstitial lung disease (ILD) with or without rapid progression, are a type of myositis-specific autoantibody. Since rapid progressive-ILD (RP-ILD) with anti-MDA5 antibodies is refractory and fatal, intensive immunosuppressive therapy with. Anti-melanoma differentiation-associated protein (MDA) 5 (anti-MDA5)-positive amyopathic dermatomyositis (ADM)-associated interstitial lung disease (ILD) (hereafter, ADM-ILD) is a rapidly. anti-aminoacyl- tRNA synthetase antibody-positive (anti-ARS)-polymyositis (PM)/DM/CADM-ILD, and the potential of serum chitotriosidase as a prognostic biomarker in anti-MDA5-positive DM/CADM-ILD as ssessed. Results. The median serum chitotriosidase level in patients with anti-MDA5-positive The combination of anti-Ro52 antibody status and anti-MDA5 antibody levels further stratified patients' survival rates, showing that the survival rate of patients who were dual positive for anti-MDA5 antibody and anti-Ro52 antibody was significantly lower than patients with mild positive anti-MDA5 antibody alone (59.9% vs 100%; P = 0.019)

Similarities between COVID-19 and anti-MDA5 syndrome: what

Serum KL‐6 level is a prognostic marker in patients with anti‐MDA5 antibody‐positive dermatomyositis associated with interstitial lung disease Yan Ye Department of Rheumatology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, Chin [18]. Gono T, Sato S, Kawaguchi Y, et al. Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Rheumatology (Oxford) 2012;51:1563-70 Effective Administration of Rituximab in Anti-MDA5 Antibody-Positive Dermatomyositis with Rapidly Progressive Interstitial Lung Disease and Refractory Cutaneous Involvement: A Case Report and Literature Review. Table 1. Summarized clinical profiles in patients of anti-MDA5-antibody-positive DM with ILD who were treated with rituximab

Effective Administration of Rituximab in Anti-MDA5

  1. The pathogenesis of anti-MDA5 antibody-positive DM/CADM-ILD is not yet fully understood; however, involvement of the macrophage activation has been recently reported [40,43,44,45]. In fatal cases of rapidly progressive ILD with anti-MDA5 antibody-positive CADM, systemic activation of the macrophages is observed in many organs
  2. Nishioka A, Tsunoda S, Abe T, et al. Serum neopterin as well as ferritin, soluble interleukin-2 receptor, KL-6 and anti-MDA5 antibody titer provide markers of the response to therapy in patients with interstitial lung disease complicating anti-MDA5 antibody-positive dermatomyositis
  3. The anti-MDA5 antibody was detected in 31 patients. DNA samples were obtained from 17 patients with the anti-MDA5 antibody, and all of these patients were enrolled in this study. All of the enrolled patients suffered from skin rashes, myopathy, or respiratory symptoms (or a combination thereof) upon admission
  4. Circulating TFH cells is correlated with disease activity in anti-MDA5 antibody positive idiopathic inflammatory myopathies M. Zhou 1 , M. Li 2 , C. Guo 3 , S. Wang 4 , X. Li 5 , S. Zhao 6 , H. Zhang 7 , N. Yang
  5. Because the presence of the anti-MDA5 antibody is a strong predictor of a worse prognosis, combination treatment with glucocorticoids (GCs) and calcineurin inhibitors (CNIs; tacrolimus (TAC) or cyclosporin A (CsA)) is recommended for patients with anti-MDA5 antibody-positive DM/CADM-ILD

Clinical characteristics of anti‐MDA5 antibody‐positive

Serum sCD163 levels decreased significantly following treatment in all patient groups (p = 0.003). Conclusion. The present results suggest an association of serum sCD163 with PM, classic DM, and CADM, especially in anti-MDA5 antibody-positive cases. However, serum sCD163 levels were not specifically associated with ILD or RP-ILD Clinical associations of anti-MDA5 antibody positive patients were analysed. Results Anti-MDA5 antibodies were identified in 5/76 (7%) PM/DM cases and all 5 cases were CADM; anti-MDA5 was the second most common autoantibody in DM after anti-MJ/NXP-2, found in 24% of cases. Compared to 29 anti-MDA5 (-) DM sis of anti-MDA5 antibody-positive clinically amyopathic dermatomyositis (CADM) associated with ILD was made (6, 7). Physical and laboratory findings were negative for other comorbid connective tissue diseases. The clinical course of the patient is depicted in Fig. 6. Given the possibility of his condition being the early phas Anti-melanoma differentiation-associated gene 5 (anti-MDA5) antibody is associated with rapidly progressive interstitial lung disease (RP-ILD) in patients with clinically amyopathic dermatomyositis (CADM) or dermatomyositis (DM). We herein report three Japanese cases of anti-MDA5 antibody-positive RP-ILD without signs of CADM or DM. High-resolution computed tomography revealed patchy or.

Background Positive anti-melanoma differentiation-associated gene 5 (MDA5) antibody has been reported in 50%-73% of patients with clinical amyopathic dermatomyositis (CADM)1. About half of MDA5 +CADM patients die of rapid progressive interstitial lung disease (RP-ILD), defined as worsening dyspnea within 1 month that required high-flow oxygen therapy or ventilator support in previously. -MDA5 antibody-positive hypomyopathic DM complicated with RP-ILD and pneumomediastinum, which was resistant to high-dose steroids but was treated successfully with combined immuno-suppressive agents including tacrolimus. We also show reduction in anti-MDA5 antibody levels in line with the improvement of RP-ILD following thes finding in anti-MDA5 antibody-positive RP-ILD, consider-ing the previous reports and the present case. This is the first case which confirms the pathological findings of RP-ILD with anti-MDA5 antibody. To date, there are 8 reported cases evaluating the pathological findings of RP-ILD with anti-MDA5 antibody (Table) (6-13). All 8 cases met the cri The patient later gained anti-MDA5 ILD associated features during an acute exacerbation phase, at which time only anti-MDA5 antibodies were positive . In contrast to these previous two cases of anti-ARS antibodies with co-existent anti-MDA5, our patient's chest CT had extensive ground glass opacities bilaterally without bronchiectasis, which. As yet, no direct-acting antiviral drugs have demonstrated efficacy in the disease. In contrast, increasing evidence indicates an immune-mediated pathophysiology that is paving the way for the evaluation of immunomodulation strategies [2]. In support of this view, we would like to highlight the striking similarities between COVID-19 and a rare autoimmune disease: the anti-MDA5-syndrome

Late Diagnosis of Anti-mda5 Antibody-positive Rapidly

  1. istration of Rituximab in Anti-MDA5 Antibody-Positive Dermatomyositis with Rapidly Progressive Interstitial Lung Disease and Refractory Cutaneous Involvement: A Case Report and Literature Review.(Case Report, Clinical report) by Case Reports in Rheumatology; Health, general B cells Corticosteroids Care and treatment Case studies Diagnosis Glucocorticoids.
  2. In conclusion, we encountered a patient with anti-MDA5 antibody-positive dermatomyositis complicated by AAHS whom we treated successfully with plasmapheresis in addi-tion to immunosuppressants. Hyperferritinemia is an essen-tial marker for anti-MDA5 antibody-positive dermatomyosi
  3. Anti-MDA5 antibody was detected in 18 patients with DM (n = 60). Anti-ARS/anti-SSA/Ro52 antibodies were detected in 31 and 39 patients with PM/DM (n = 84). Rapidly progressive ILD patients were mainly found in the anti-MDA5 antibody-positive DM group. During the follow-up period, 9 patients died

Distinct Phenotypes Observed in Anti-MDA5 Positive

Treatment of a case with anti-MDA5 antibody positive

Serum Cytokine Profiles of Patients with Interstitial LungA7446 - Prognostic Significance of Macrophage-MannoseProposed criteria that may be used in clinical practice toComprehensive assessment of myositis-specific北里大学医学部 膠原病・感染内科学 - Home | FacebookAnti-MX1 antibody (ab95926) | Abcam

Both studies reported anti-MDA5 antibody to be strongly associated with ILD; however, only 8 (18%) of the 44 Japanese cases and none of the UK patients developed RP-ILD. A recent cohort study in the UK observed low myositis severity scores depending on muscle biopsies in 11 anti-MDA5 antibody-positive patients 15 the anti-MDA5 antibody is a strong predictor of a worse prognosis, combination treatment with glucocorticoids (GCs) and calcineurin inhibitors (CNIs; tacrolimus (TAC) or cyclosporin A (CsA)) is recommended for patients with anti-MDA5 antibody-positive DM/CADM-ILD. Rapidly progressiv Methods This retrospective study included 30 patients with anti-MDA5-positive DM/CADM-ILD. The clinical characteristics and laboratory findings at the time of diagnosis were analyzed. Serum chitotriosidase levels were measured in the 30 patients, in 21 healthy controls, and in 25 patients with anti-aminoacyl- tRNA synthetase antibody-positive (anti-ARS)-polymyositis (PM)/DM/CADM-ILD, and. Endo Y, Koga T, Suzuki T, Hara K, Ishida M, Fujita Y, et al. Successful treatment of plasma exchange for rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis: a case report. Medicine. 2018;97(15):e0436. Article Google Scholar 30 Ogawa Y, Kishida D, Shimojima Y, et al. Effective administration of rituximab in anti-MDA5 antibody-positive dermatomyositis with rapidly progressive interstitial lung disease and refractory cutaneous involvement: a case report and literature review. Case Rep Rheumatol. 2017; 2017:5386797. Google Scholar; 38